GONO Foundation is a no-profit group of Italian Investigators committed to design & conduct of academic clinical trials in oncology
Joined April 2021
- Tweets88
- Following123
- Followers270
- Likes226
GONO Foundation retweeted
Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients
👉 rdcu.be/d0AHE
@ChiaraCrem1 @VStudiale @carlottanto1 @NatRevClinOncol
GONO Foundation retweeted
Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX HER2-negative GC/GEJ cancer
@TheLancetOncol
doi.org/10.1016/S1470-2045(2…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts who are not eligible for ICI/🎯💊
@myESMO
GONO Foundation retweeted
KRASG12D-Mutated Metastatic #ColorectalCancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration: brnw.ch/21wOBSV @ChiaraCrem1, @FoundationGono #CRCSM
GONO Foundation retweeted
The one & only one @Raffa_Casolino 🇺🇳 delivering the Keynote lecture at @AIOMtweet meeting in #Venice right now !
✨ An illuminating perspective on #Cancer control amidst Humanitarian Challenges ✨
@WHO #UHC
@AiomFondazione #LeGiornateDellEtica #SanServolo
GONO Foundation retweeted
☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer
@eClinicalMed
➡️45 patients
✅R0 resection: 80% vs. 20%, P < 0.001
✅3-year PFS: 76% vs. 45% , P = 0.049
✅3-year OS: 87.6% vs. 75% , P = 0.037
✅No differences in severe AEs
❗️Study was terminated prematurely because of R0 resection benefit of CRT
👉doi.org/10.1016/j.eclinm.202…
@TheLancetOncol @TheLancet @LancetGastroHep @myESMO @OncoAlert #cancer #oncology #MedX
GONO Foundation retweeted
How long should we treat our pts with MSI-H #mCRC with immune checkpoint inhibitors to preserve efficacy while optimizing toxicities and costs?
In our academic international study 🇮🇹🇫🇷🇺🇸 ETD within 1 year is not detrimental vs a longer duration. RCT are now warranted🔜
#ESMO24
GONO Foundation retweeted
Un successo il Congresso Nazionale di AIOM Giovani 2024. Un grande lavoro del Working Group giovani.
#AIOM #CongressoNazionaleAIOMgiovani
GONO Foundation retweeted
Promising combination for mCRC patients not fit for classical 1st line doublet chemo, personally I love this trial by @FoundationGono ! – at Munich, Germany
Such a great opportunity to present the results from the phase 1 of the TriComB study by @FoundationGono at #ESMOGI24 @myESMO
Thank you prof. @ChiaraCrem1 for being the best mentor ever!
GONO Foundation retweeted
Best colleagues and friends ever! Ready for Atezo2!
🚨New Paper Alert! AtezoTRIBE Study🚨
@JCO_ASCO @LisaSalvy @FilippoPietran4 @ChiaraCrem1 @sara_lonardi1 @erikamartin3lli @IlBuonRossini @carlottanto @FoundationGono
oncodaily.com/89011.html
Summary by @amalsargsyan
#Cancer #CancerTreatment #CRCsm #OncoDaily #Oncology
GONO Foundation retweeted
Updated and OS results of Atezotribe by @FoundationGono 🇮🇹 Confirmed role of IS IC as biomarker of ICI sensitivity in pMMR mCRC. @carlottanto @FilippoPietran4 @lonardi_sara @LisaSalvy @IlBuonRossini ascopubs.org/doi/10.1200/JCO…
GONO Foundation retweeted
ESOPEC trial
It’s been a long 15 year journey, but so nice to see Docetaxel triplets come on top for the benefit of our patients!
CROSS just doesn’t work for GEA-EAC- radiation compensates for poor surgical control (trans-hiatal) and CM577 compensates for poor systemic control
GONO Foundation retweeted
Big year for gastroesophageal at #ASCO24 @ASCO
ESOPEC plenary
EA2174, ARMANI, and RENAISSANCE in the oral sessions. @KarynAGoodman @NataliyaUboha @FilippoPietran4 @eaonc @LFerri123 @FlorianLordick @YJanjigianMD @KoheiShitara @sara_lonardi1 @LizzySmyth1 @sundar__raghav
GONO Foundation retweeted
What are the treatment patterns and outcomes for patients with BRAF-mutant mCRC after progression to encorafenib/cetiximab? In this article, Dr. Germani et al. report data from a large 🇮🇹 cohort, suggesting improved outcomes when TT is administered early. esmoopen.com/article/S2059-7…
GONO Foundation retweeted
Very important data in light of the ongoing PURITY study (NCT06037980) by @Mom_enji and @FoundationGono
🔎Intrahepatic cholangiocarcinoma (IHCC)
✅Neoadjuvant gemcitabin, cisplatin and nab-paclitaxel (NEO-GAP)
@AnnSurgOncol
➡️A single arm, phase II trial
➡️30 patients, resectable but high-risk (tumor size > 5 cm, multiple tumors, presence of radiographic major vascular invasion, or lymph node involvement )
➡️4cycle GAP
➡️disease control rate: 90% (23% PR, 67% stable)
➡️73% completed all chemo and surgery (p=0.008)
➡️Median RFS: 7.1 mo
➡️Median OS: 24 mo (nit reached in patients who underwent surgery)
➡️grade ≥ 3 treatment-related AE (33% patients, neutropenia and diarrhea)
➡️50% required dose reduction
✅Neoadjuvant GAP may be feasible in IHCC
👉link.springer.com/article/10…
@ASCO @myESMO @curecc @CCA_Alliance @CholangioNet @c3_cholangio @CrainesCrew @NCICCR_SurgOnc @SocSurgOnc @ESSOnews @MayoClinicGIHep @DrAngelaLamarca @ArndtVogel @DrHaleyEllis @CentralParkWMD @AmerGastroAssn @GIcancerDoc @TsungCheWu @BCLC_group @PrecisionBTCnet @CcaEns @oncodaily @csoncol @oncologytube @SWOG @MDAndersonNews @WinshipAtEmory @OHSUKnight
#Cancer #Oncology #cholangiocarcinoma #biliarytract #CancerTreatment #MedX
GONO Foundation retweeted
AI-assisted transcriptomic signatures: a key step in personalizing pancreatic cancer treatment.
: jle.com/en/revues/ito/e-docs…
GONO Foundation retweeted
Happy to share latest international collaboration led by awesome @arnavmehta3 @AnMinae and others. @JeeyunM @CD_AACR @SU2Cscience
Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric. aacrjournals.org/cancerdisco…
GONO Foundation retweeted
Early onset GI cancers will be highlighted at @ASCO #GI24
EO-EGC is rising along with CRC. Our results in @JNCI_Now show EO-EGC is:
⬆️gastric ⬆️diffuse type
🟰 stage/survival
Much still unknown
Fantastic collaboration @AndreaCercek @YJanjigianMD @SteveMaronMD @MSKCancerCenter
GONO Foundation retweeted
Paper 2:
Phase 3 trial of KRAS G12C inhibitor #sotorasib + #panitumumab demonstrated ⬆️ PFS in patients with chemo-refractory metastatic colorectal cancer.
@NEJM @mgfakih @FilippoPietran4
nejm.org/doi/full/10.1056/NE…
GONO Foundation retweeted
@SirohiBhawna, I worked with Venkata on a project and he was amazing! He coordinated 41 colleagues from India in the translation of patient information sheets for Biliary Cancers into 13 Indian languages. thelancet.com/journals/lanon…
